TCM
OKUR

Tybourne Capital Management’s OnKure Therapeutics OKUR Stock Holding History

Tybourne Capital Management’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-70,000
Closed -$2.06M – 29
2022
Q1 		$2.06M Sell
70,000
-5,000
-7% -$280K 0.12% 29
2021
Q4 		$6.41M Hold
75,000
– – 0.19% 24
2021
Q3 		$5.59M Hold
75,000
– – 0.14% 23
2021
Q2 		$7M Buy
+75,000
New +$8.36M 0.15% 27

Other funds holding OKUR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Tybourne Capital Management's OKUR Position: Q2 2022 in Review

Tybourne Capital Management sold out of OnKure Therapeutics (OKUR) in Q2 2022, closing a stake of 70,000 shares — an estimated $2.06M sold.

Tybourne Capital Management first reported a position in OKUR in Q2 2021 and held it in 4 quarters. The position peaked at $7M in Q2 2021. 33 funds tracked by Wall St. Rank hold OKUR as of Q2 2022.

  • Tybourne Capital Management reported no remaining OnKure Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Tybourne Capital Management sold 70,000 OnKure Therapeutics shares in Q2 2022, an estimated $2.06M.
  • Tybourne Capital Management first reported a position in OnKure Therapeutics in Q2 2021 and held it in 4 quarters.
  • Tybourne Capital Management's OnKure Therapeutics position peaked at $7M in Q2 2021.
  • 33 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2022.

Based on Tybourne Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.